These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32798077)

  • 1. Efficacy of bezafibrate for preventing myopathic attacks in patients with very long-chain acyl-CoA dehydrogenase deficiency.
    Shiraishi H; Yamada K; Egawa K; Ishige M; Ochi F; Watanabe A; Kawakami S; Kuzume K; Watanabe K; Sameshima K; Nakamagoe K; Tamaoka A; Asahina N; Yokoshiki S; Kobayashi K; Miyakoshi T; Oba K; Isoe T; Hayashi H; Yamaguchi S; Sato N
    Brain Dev; 2021 Feb; 43(2):214-219. PubMed ID: 32798077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned?
    Bastin J; Bonnefont JP; Djouadi F; Bresson JL
    J Inherit Metab Dis; 2015 Mar; 38(2):371-2. PubMed ID: 25310995
    [No Abstract]   [Full Text] [Related]  

  • 3. No effect of bezafibrate in patients with CPTII and VLCAD deficiencies.
    Ørngreen MC; Vissing J; Laforét P
    J Inherit Metab Dis; 2015 Mar; 38(2):373-4. PubMed ID: 25331908
    [No Abstract]   [Full Text] [Related]  

  • 4. Proposal for an individualized dietary strategy in patients with very long-chain acyl-CoA dehydrogenase deficiency.
    Bleeker JC; Kok IL; Ferdinandusse S; de Vries M; Derks TGJ; Mulder MF; Williams M; Gozalbo ER; Bosch AM; van den Hurk DT; de Sain-van der Velden MGM; Waterham HR; Wijburg FA; Visser G
    J Inherit Metab Dis; 2019 Jan; 42(1):159-168. PubMed ID: 30740737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bezafibrate activation of PPAR drives disturbances in mitochondrial redox bioenergetics and decreases the viability of cells from patients with VLCAD deficiency.
    Lund M; Andersen KG; Heaton R; Hargreaves IP; Gregersen N; Olsen RKJ
    Biochim Biophys Acta Mol Basis Dis; 2021 Jun; 1867(6):166100. PubMed ID: 33549744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.
    Yamada K; Taketani T
    J Hum Genet; 2019 Feb; 64(2):73-85. PubMed ID: 30401918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered Energetics of Exercise Explain Risk of Rhabdomyolysis in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency.
    Diekman EF; Visser G; Schmitz JP; Nievelstein RA; de Sain-van der Velden M; Wardrop M; Van der Pol WL; Houten SM; van Riel NA; Takken T; Jeneson JA
    PLoS One; 2016; 11(2):e0147818. PubMed ID: 26881790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological Abnormalities in VLCAD Deficient hiPSC-Cardiomyocytes Can Be Improved by Lowering Accumulation of Fatty Acid Oxidation Intermediates.
    Knottnerus SJG; Mengarelli I; Wüst RCI; Baartscheer A; Bleeker JC; Coronel R; Ferdinandusse S; Guan K; IJlst L; Li W; Luo X; Portero VM; Ulbricht Y; Visser G; Wanders RJA; Wijburg FA; Verkerk AO; Houtkooper RH; Bezzina CR
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32276429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult-onset very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD).
    Fatehi F; Okhovat AA; Nilipour Y; Mroczek M; Straub V; Töpf A; Palibrk A; Peric S; Rakocevic Stojanovic V; Najmabadi H; Nafissi S
    Eur J Neurol; 2020 Nov; 27(11):2257-2266. PubMed ID: 32558070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.
    Ørngreen MC; Madsen KL; Preisler N; Andersen G; Vissing J; Laforêt P
    Neurology; 2014 Feb; 82(7):607-13. PubMed ID: 24453079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very long-chain acyl-coenzyme A dehydrogenase deficiency in Chinese patients: eight case reports, including one case of prenatal diagnosis.
    Li X; Ding Y; Ma Y; Liu Y; Wang Q; Song J; Yang Y
    Eur J Med Genet; 2015 Mar; 58(3):134-9. PubMed ID: 25652019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and cellular pathology of very-long-chain acyl-CoA dehydrogenase deficiency.
    Schiff M; Mohsen AW; Karunanidhi A; McCracken E; Yeasted R; Vockley J
    Mol Genet Metab; 2013 May; 109(1):21-7. PubMed ID: 23480858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
    Djouadi F; Aubey F; Schlemmer D; Ruiter JP; Wanders RJ; Strauss AW; Bastin J
    Hum Mol Genet; 2005 Sep; 14(18):2695-703. PubMed ID: 16115821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and clinical characteristics of very-long-chain acyl-CoA dehydrogenase deficiency: A single-center experience in Saudi Arabia.
    Alhashem A; Mohamed S; Abdelraheem M; AlGufaydi B; Al-Aqeel A
    Saudi Med J; 2020 Jun; 41(6):590-596. PubMed ID: 32518924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare Korean Cases of Very-long-chain Acyl-CoA Dehydrogenase Deficiency with a Novel Recurrent Mutation.
    Ko JM; Seo J; Choi M; Song J; Lee KA; Shin CH
    Ann Clin Lab Sci; 2016; 46(1):97-101. PubMed ID: 26927351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic challenge in very-long chain acyl-CoA dehydrogenase deficiency (VLCADD).
    Hesse J; Braun C; Behringer S; Matysiak U; Spiekerkoetter U; Tucci S
    J Inherit Metab Dis; 2018 Nov; 41(6):1169-1178. PubMed ID: 30194637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscle MRI in patients with long-chain fatty acid oxidation disorders.
    Diekman EF; van der Pol WL; Nievelstein RA; Houten SM; Wijburg FA; Visser G
    J Inherit Metab Dis; 2014 May; 37(3):405-13. PubMed ID: 24305961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatty acid oxidation flux predicts the clinical severity of VLCAD deficiency.
    Diekman EF; Ferdinandusse S; van der Pol L; Waterham HR; Ruiter JP; Ijlst L; Wanders RJ; Houten SM; Wijburg FA; Blank AC; Asselbergs FW; Houtkooper RH; Visser G
    Genet Med; 2015 Dec; 17(12):989-94. PubMed ID: 25834949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of Lipistart, a medium-chain triglyceride based formula, in the dietary treatment of long-chain fatty acid disorders: a phase I study.
    MacDonald A; Webster R; Whitlock M; Gerrard A; Daly A; Preece MA; Evans S; Ashmore C; Chakrapani A; Vijay S; Santra S
    J Pediatr Endocrinol Metab; 2018 Mar; 31(3):297-304. PubMed ID: 29425111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful management of pregnancy with very-long-chain acyl-coenzyme A dehydrogenase deficiency.
    Yamamoto H; Tachibana D; Tajima G; Shigematsu Y; Hamasaki T; Tanaka A; Koyama M
    J Obstet Gynaecol Res; 2015 Jul; 41(7):1126-8. PubMed ID: 25655073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.